US EditionSelvita Acquires License for Medicines Discovery Catapult’s Patented Target Engagement Technology
Summary by Selvita
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Selvita Acquires License for Medicines Discovery Catapult’s Patented Target Engagement Technology
The Chemical Protein Stability Assay generates vital data to support drug discovery innovators and will enhance Selvita’s screening platform Kraków, Poland – 27 May 2025 – Selvita is the first contract research organisation (CRO) to license a Chemical Protein Stability Assay developed and patented by Medicines Discovery Catapult (MDC) to help identify and prioritise drug candidates faster. MDC’s Chemical Protein Stability Assay (CPSA) is a disti…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
